2024
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitorsInconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer
Sundar R, Smyth E. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer. The Lancet Gastroenterology & Hepatology 2024, 9: 495-497. PMID: 38492581, DOI: 10.1016/s2468-1253(24)00043-8.Peer-Reviewed Original Research
2022
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”
Yeong J, Teo C, Tay R, Tan B, Chan Y, Smyth E, Sundar R. Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”. Gastric Cancer 2022, 25: 1133-1135. PMID: 36152122, DOI: 10.1007/s10120-022-01343-4.Peer-Reviewed Original ResearchChoice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenBiomarkers, TumorCross-Sectional StudiesHumansImmunohistochemistryImmunotherapyStomach NeoplasmsConceptsCombined positive scorePD-L1 combined positive scoreTumor proportion scorePD-L1Gastric cancerImmune cellsPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentBackgroundImmune checkpoint inhibitorsGastric cancer immunotherapyPD-L1 positivityPD-L1 scoringPD-L1 immunohistochemistryDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceCheckpoint inhibitorsDako 22C3ICI therapyCross-sectional studyCancer immunotherapyPatient selectionPhase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim J, Wong A, Ow S, Ngoi N, Chan G, Ang Y, Chong W, Lim S, Lim Y, Lee M, Choo J, Tan H, Yong W, Soo R, Tan D, Chee C, Sundar R, Yadav K, Jain S, Wang L, Tai B, Goh B, Lee S. Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research 2022, 28: 2248-2256. PMID: 35363275, DOI: 10.1158/1078-0432.ccr-21-4179.Peer-Reviewed Original ResearchConceptsBreast cancerDose expansionEstrogen receptorHormone receptor-positive breast cancerPhase II dose expansionRecommended phase II doseReceptor-positive breast cancerCDK4/6 inhibitor therapyDose-expansion studyPaired tumor biopsiesPhase Ib/II trialPhase II doseVascular normalization indexTreated with lenvatinibDose of lenvatinibER+/HER2- breast cancerMetastatic breast cancerPreliminary antitumor activityEstrogen-responsive genesLenvatinib combinationII doseMetastatic settingInhibitor therapyMultikinase inhibitorTumor biopsies
2021
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer
An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.Peer-Reviewed Original ResearchConceptsAdvanced gastric cancerRNA editingRNA editing signaturesEditing levelsGastric cancerRNA editing eventsHigher editing levelsAdenosine-to-inosineRNA editing analysisGastric cancer cell linesPredictive biomarkersStratify patientsLevels of editingGene expression profilesPredicting response to chemotherapyEditing sitesEditing eventsMolecular subtypes of gastric cancerCancer cell linesPlatinum-based chemotherapyMetastatic gastric cancerSubtypes of gastric cancerCancer Genome AtlasFirst-line therapyResponse to chemotherapy
2019
Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.
Sundar R, Tan I, Chee C. Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal Of Clinical Oncology 2019, 37: 3066-3068. PMID: 31550189, DOI: 10.1200/jco.19.01977.Peer-Reviewed Original Research
2018
Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes
Sundar R, Qamra A, Tan A, Zhang S, Ng C, Teh B, Lee J, Kim K, Tan P. Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer 2018, 21: 1064-1070. PMID: 29915957, DOI: 10.1007/s10120-018-0851-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedB7-H1 AntigenBiomarkers, TumorCD8 AntigensCohort StudiesDisease-Free SurvivalEpstein-Barr Virus InfectionsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHerpesvirus 4, HumanHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMaleMiddle AgedPerforinProgrammed Cell Death 1 ReceptorStomach NeoplasmsConceptsPD-L1PD-L1highPD-L1lowEBVaGC samplesImmune-related genesAssociated with worse disease-free survivalGastric cancerPD-L1 immunohistochemistry expressionPD-L1 transcript expressionExpression of PD-L1Levels of PD-L1Epstein-Barr virus-associated gastric cancerTumour-infiltrating lymphocyte patternPD-L1 expressionPD-L1 immunohistochemistryPrimary tumor resectionDisease-free survivalAssociated with higher expressionCases of EBVaGCGastric cancer patientsEBV-negative samplesSamsung Medical CentreAsian Cancer Research GroupImmune genesCancer Research GroupAtaxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorColorectal NeoplasmsDNA RepairFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedOxaliplatinPrognosisRetrospective StudiesSurvival RateYoung AdultConceptsATM lossColorectal cancerAssociated with superior overall survivalDNA repair targeting agentsMetastatic colorectal cancer patientsAtaxia telangiectasiaIrinotecan-based therapySuperior overall survivalOxaliplatin-based therapyOxaliplatin-based chemotherapyTreatment of colorectal cancerATM protein expressionClinical outcome dataNuclear staining intensityColorectal cancer patientsDrug Development UnitColorectal cancer samplesOverall survivalMutation statusH-scoreTargeted agentsClinical outcomesDNA repair signalingTumor samplesCancer patientsBiomarkers for Homologous Recombination Deficiency in Cancer
Hoppe M, Sundar R, Tan D, Jeyasekharan A. Biomarkers for Homologous Recombination Deficiency in Cancer. Journal Of The National Cancer Institute 2018, 110: 704-713. PMID: 29788099, DOI: 10.1093/jnci/djy085.Peer-Reviewed Original ResearchConceptsPoly-ADP-ribose polymeraseArray-based comparative genomic hybridizationSingle nucleotide polymorphismsHomologous recombination deficiencyPoly-ADP ribose polymerase inhibitorsComparative genomic hybridizationHomologous recombination genesNext-generation sequencingDNA repair pathwaysRecombination deficiencyClinical trialsGenomic hybridizationGermline BRCA1/2 mutation statusClinical development of PARP inhibitorsDefective DNA repairGenomic scarsResponse to platinum-based therapyHomologous recombinationDevelopment of PARP inhibitorsRecombinant genesNucleotide polymorphismsPlatinum-based therapyRibose polymeraseBRCA1/2 mutation statusDNA repair
2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Original ResearchConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypes
2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.Peer-Reviewed Original ResearchConceptsPrecision medicineNext-generation sequencingMechanisms of drug resistanceField of immunotherapyManagement of cancer patientsOptimize treatment efficacyAntitumor responseIntertumoral heterogeneityClonal evolutionTargeted agentsMinimal toxicityDrug resistanceCancer patientsTreatment efficacyBiomarker developmentBiomarker discoveryCancer researchCancerCompounds promisesImmunotherapyMedicinePhase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
Wong A, Sundar R, Wang T, Ng T, Zhang B, Tan S, Soh T, Pang A, Tan C, Ow S, Wang L, Mogro J, Ho J, Jeyasekharan A, Huang Y, Thng C, Chan C, Hartman M, Iau P, Buhari S, Goh B, Lee S. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016, 7: 64089-64099. PMID: 27577069, PMCID: PMC5325427, DOI: 10.18632/oncotarget.11596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnthracyclinesAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsContrast MediaCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFemaleHumansImmunohistochemistryIndolesMagnetic Resonance ImagingMiddle AgedNeoadjuvant TherapyPreoperative PeriodPyrrolesSunitinibTreatment OutcomeConceptsPathological complete responseVascular normalization indexChemotherapy dose delaysLow-doseDose delaysDCE-MRIPhase IbDecreased lymphatic vessel densityIntra-tumoral drug deliveryPathologic complete response rateRecommended phase II dosePhase II doseDose of sunitinibTreatment of breast cancerDCE-MRI parametersPre-operative treatmentAnthracycline-based chemotherapyOpen-label studyRandomized to chemotherapyTumor vessel normalizationLymphatic vessel densityEnhance chemotherapy efficacyBreast cancer patientsFunctional imaging biomarkersPharmacodynamic evidence